Samsara BioCapital Amends Kalaris (KLRS) Filing

Samsara BioCapital, L.P. filed an Amendment No. 3 to its Schedule 13D on May 22, 2026, regarding its holdings in Kalaris Therapeutics, Inc. (KLRS). The filing details several internal transactions and distributions effective May 20, 2026. Specifically, Samsara Opportunity Fund purchased 244,300 shares from Samsara LP in a private sale at $4.83 per share to address interests of redeeming limited partners. Additionally, Samsara LP executed a pro rata in-kind distribution of 66,906 shares for no consideration. Following these transactions, Samsara BioCapital, L.P. directly holds 10,657,028 shares, representing a 44.8% ownership stake. Dr. Srinivas Akkaraju, as the managing member of the involved general partners, is deemed to have shared voting and dispositive power over a total of 12,900,583 shares (including options), representing approximately 54.2% of the company. The reporting persons maintain their significant influence over the issuer through these consolidated holdings across various Samsara-affiliated entities.